Vir Biotechnology is now a two-engine company, with major pharma partnerships and a fully enrolled hepatitis delta phase 3 ...
Fidelity offers lower costs and steadier returns, while State Street targets smaller biotech companies with higher volatility ...
23mOpinion
Worcester’s bet on biotech is paying off
WORCESTER — On a Thursday in March, Jon Weaver, president and CEO of Massachusetts Biomedical Initiatives, had what he calls ...
Comparing the Vanguard Health Care ETF (NYSEMKT:VHT) and iShares Biotechnology ETF (NASDAQ:IBB) involves weighing a broad, ...
Partnership includes development and manufacturing support for multiple monoclonal and bispecific antibody programs ...
Vir Biotechnology has appointed Aziz Sawaf as Executive Vice President and Chief Financial Officer, effective October 5, 2026 ...
Nautilus Biotechnology Inc. stocks have been trading up by 15.14 percent amid heightened investor optimism from its latest ...
The FDA has taken important steps through Operation TrialBlazer and stronger scrutiny of foreign clinical data, but more must ...
(Nasdaq: VIR) today announced the appointment of Aziz Sawaf, MBEE, MBA, CFA, as Executive Vice President and Chief Financial ...
Magnesium has quietly become one of the most talked-about minerals in nutrition science, and a new narrative review published ...
Healthcare stocks underperformed the broader market in September, with the Health Care Select Sector SPDR Fund falling 1.89% ...
The average one-year price target for Genfit (XTRA:XUP) has been revised to 6,92 € / share. This is an increase of 37.92% from the prior estimate of 5,02 € dated September 13, 2026. These figures ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results